Author

Ákos Iliás

USTEKINUMAB IS ASSOCIATED WITH SUPERIOR TREATMENT PERSISTENCE BUT NOT WITH HIGHER REMISSION RATES COMPARED TO VEDOLIZUMAB IN REFRACTORY CROHN’S DISEASE PATIENTS: RESULTS FROM A MULTICENTRE COHORT STUDY
USTEKINUMAB IS ASSOCIATED WITH SUPERIOR TREATMENT PERSISTENCE BUT NOT WITH HIGHER REMISSION RATES COMPARED TO VEDOLIZUMAB IN REFRACTORY CROHN’S DISEASE PATIENTS: RESULTS FROM A MULTICENTRE COHORT STUDY

Ákos Iliás  et al.

INCIDENCE, PREDICTIVE FACTORS AND OUTCOMES OF NON-VARICEAL UPPER GASTROINTESTINAL BLEEDING: A PROSPECTIVE MULTICENTER POPULATION-BASED STUDY FROM HUNGARY
INCIDENCE, PREDICTIVE FACTORS AND OUTCOMES OF NON-VARICEAL UPPER GASTROINTESTINAL BLEEDING: A PROSPECTIVE MULTICENTER POPULATION-BASED STUDY FROM HUNGARY

Ákos Iliás  et al.

INCIDENCE, PREDICTIVE FACTORS AND OUTCOMES OF VARICEAL UPPER GASTROINTESTINAL BLEEDING - A PROSPECTIVE MULTICENTER POPULATION-BASED STUDY FROM HUNGARY
INCIDENCE, PREDICTIVE FACTORS AND OUTCOMES OF VARICEAL UPPER GASTROINTESTINAL BLEEDING - A PROSPECTIVE MULTICENTER POPULATION-BASED STUDY FROM HUNGARY

Ákos Iliás  et al.

NON-MEDICAL, MANDATORY SWITCH AMONG ADALIMUMAB BIOSIMILARS AND FROM THE ORIGINATOR ADALIMUMAB TO BIOSIMILARS IN INFLAMMATORY BOWEL DISEASE PATIENTS – A PROSPECTIVE, MULTICENTRE STUDY ON EFFICACY, DRUG SUSTAINABILITY AND SAFETY
NON-MEDICAL, MANDATORY SWITCH AMONG ADALIMUMAB BIOSIMILARS AND FROM THE ORIGINATOR ADALIMUMAB TO BIOSIMILARS IN INFLAMMATORY BOWEL DISEASE PATIENTS – A PROSPECTIVE, MULTICENTRE STUDY ON EFFICACY, DRUG SUSTAINABILITY AND SAFETY

Ákos Iliás  et al.

CLINICAL EFFICACY, DRUG SUSTAINABILITY AND RESULTS FROM THERAPEUTIC DRUG MONITORING IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB - 1-YEAR FOLLOW-UP OF A PROSPECTIVE, NATIONWIDE, MULTICENTER COHORT FROM HUNGARY
CLINICAL EFFICACY, DRUG SUSTAINABILITY AND RESULTS FROM THERAPEUTIC DRUG MONITORING IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB - 1-YEAR FOLLOW-UP OF A PROSPECTIVE, NATIONWIDE, MULTICENTER COHORT FROM HUNGARY

Ákos Iliás  et al.

Item 1 - 5 / 5
1